Daiichi Sankyo Moves Forward On Antibody Drug For Multiple Cancers
This article was originally published in PharmAsia News
Daiichi Sankyo is pressing forward with its simultaneous trials of four different antibody drugs to treat several types of cancers
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.